General Information of Drug Combination (ID: DC2VJ7T)

Drug Combination Name
SY-1425 Hepzato
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs SY-1425   DMH8UF0 Hepzato   DM2AZPP
N.A. N.A.
High-throughput Screening Result Testing Cell Line: DU-145
Zero Interaction Potency (ZIP) Score: 2.58
Bliss Independence Score: 5.52
Loewe Additivity Score: 3.37
LHighest Single Agent (HSA) Score: 1.47

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [2]
Myelodysplastic syndrome 2A37 Phase 1 [2]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [2]
------------------------------------------------------------------------------------
Indication(s) of Hepzato
Disease Entry ICD 11 Status REF
Uveal Melanoma 2D0Y Phase 3 [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Papillary renal cell carcinoma DCGMUOJ ACHN Investigative [4]
Adenocarcinoma DC4BELG HT29 Investigative [1]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966